Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abraxis Starts Phase II Enrollment for Coroxane | Contract Pharma

What are you searching for?

Sign in

Abraxis Starts Phase II Enrollment for Coroxane

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abraxis BioScience, Inc. has initiated enrollment in its Phase II clinical trial to evaluate the efficacy and safety of Coroxane for the prevention and reduction of restenosis following revascularization of the superficial femoral artery (SFA).

Coroxane (nanometer-sized paclitaxel and Abraxane) is a novel, solvent-free, albumin-bound form of paclitaxel used for cardiovascular applications. Abraxane is the first and only approved protein-bound, nanometer-sized, solvent-free taxane and is the first commercial product to validate Abraxis’ proprietary nab technology platform. Abraxane is marketed for the treatment of breast cancer.

Earlier preclinical and clinical studies investigated the potential for Coroxane as an alternative to drug eluting stents in coronary arteries. Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis,  noted that the company currently intends to seek a strategic partner for the development and marketing of Coroxane.

Tthe Phase II trial, led by principal investigator John Rundback, M.D., director of the Interventional Institute at Holy Name Hospital in Teaneck, N.J. and Associate Professor of Clinical Radiology at Columbia University College of Physicians and Surgeons, is a randomized, open-label, prospective, multicenter study that will compare the safety and efficacy of three different Coroxane dosing schedules to primary percutaneous balloon angioplasty with provisional stenting, the standard treatment for stenosis in the SFA.

“The present study is an important step forward in providing a treatment alternative to patients with moderate to long segment SFA disease using Coroxane. The novel mode of delivery allows platform independent treatment and can be used regardless of the initial revascularization method,” said Dr. Rundback. “Since drug eluting stents have not yet clearly shown long-term benefit, a different strategy for delivering this very bioactive agent to the site of balloon injury has tremendous potential to expand the therapeutic options and improve outcomes for these patients.”

Approximately 150 patients will be monitored for restenosis of the target vessel at nine months as evaluated by angiography and duplex ultrasound.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters